Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.

Scheen, André

doi:10.1016/j.diabet.2018.10.003

Article (Scientific journals)

Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.

Scheen, André

2018 • In Diabetes and Metabolism

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/230405

DOI
10.1016/j.diabet.2018.10.003

PubMed
30477733

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2018 D&M effects on glucose lowering.pdf

Publisher postprint (585.5 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Chronic kidney disease; DPP-4 inhibitor; GLP-1 receptor agonist; Metformin; SGLT2 inhibitor; Thiazolidinedione; Type 2 diabetes

Abstract :

[en] Diabetic kidney disease (DKD) represents an enormous burden in patients with type 2 diabetes mellitus (T2DM). Preclinical studies using most glucose-lowering agents have suggested renal-protective effects, but the proposed mechanisms of renoprotection have yet to be defined, and the promising results from experimental studies remain to be translated into human clinical findings to improve the prognosis of patients at risk of DKD. Also, it is important to distinguish effects on surrogate endpoints, such as decreases in albuminuria and estimated glomerular filtration rate (eGFR), and hard clinical endpoints, such as progression to end-stage renal disease (ESRD) and death from renal causes. Data regarding insulin therapy are surprisingly scarce, and it is nearly impossible to separate the effects of better glucose control from those of insulin per se, whereas favourable preclinical data with metformin, thiazolidinediones and dipeptidyl peptidase (DPP)-4 inhibitors are plentiful, and positive effects have been observed in clinical studies, at least for surrogate endpoints. The most favourable renal results have been reported with glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter type-2 inhibitors (SGLT2is). Significant reductions in both albuminuria and eGFR decline have been reported with these classes of glucose-lowering medications compared with placebo and other glucose-lowering agents. Moreover, in large prospective cardiovascular outcome trials using composite renal outcomes as secondary endpoints, both GLP-1RAs and SGLT2is added to standard care reduced renal outcomes combining persistent macro-albuminuria, doubling of serum creatinine, progression to ESRD and kidney-related death; however, to date, only SGLT2is have been clearly shown to reduce such hard clinical outcomes. Yet, as the renoprotective effects of SGLT2is and GLP-1RAs appear to be independent of glucose-lowering activity, the underlying mechanisms are still a matter of debate. For this reason, further studies with renal outcomes as primary endpoints are now awaited in T2DM patients at high risk of DKD, including trials evaluating the potential add-on benefits of combined GLP-1RA-SGLT2i therapies.

Disciplines :

Endocrinology, metabolism & nutrition
Urology & nephrology

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

English

Title :

Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.

Publication date :

2018

Journal title :

Diabetes and Metabolism

ISSN :

1262-3636

eISSN :

1878-1780

Publisher :

Elsevier Masson, Paris, France

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 21 December 2018

Statistics

Number of views

730 (4 by ULiège)

Number of downloads

1356 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Tuttle, KR, Bakris, GL, Bilous, RW, Chiang, JL, de Boer, IH, Goldstein-Fuchs, J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis 64 (2014), 510–533.
Burke, J, Kovacs, B, Borton, L, Sander, S, Health care utilization and costs in type 2 diabetes mellitus and their association with renal impairment. Postgrad Med 124 (2012), 77–91.
Assogba, GF, Couchoud, C, Roudier, C, Pornet, C, Fosse, S, Romon, I, et al. Prevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: the ENTRED surveys (2001 and 2007). Diabetes Metab 38 (2012), 558–566.
Koye, DN, Magliano, DJ, Nelson, RG, Pavkov, ME, The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis 25 (2018), 121–132.
Alicic, RZ, Rooney, MT, Tuttle, KR., Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 12 (2017), 2032–2045.
American Diabetes Association. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2018. Diabetes Care 41 (2018), S105–S118 [10].
MacIsaac, RJ, Jerums, G, Ekinci, EI, Glycemic control as primary prevention for diabetic kidney disease. Adv Chronic Kidney Dis 25 (2018), 141–148.
Ruospo, M, Saglimbene, VM, Palmer, SC, De Cosmo, S, Pacilli, A, Lamacchia, O, et al. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev, 6, 2017, CD010137.
Scheen, AJ, Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 9 (2013), 529–550.
Roussel, R, Lorraine, J, Rodriguez, A, Salaun-Martin, C, Overview of data concerning the safe use of antihyperglycemic medications in type 2 diabetes mellitus and chronic kidney disease. Adv Ther 32 (2015), 1029–1064.
Sanchez-Rangel, E, Inzucchi, SE, Metformin: clinical use in type 2 diabetes. Diabetologia 60 (2017), 1586–1593.
Coca, SG, Ismail-Beigi, F, Haq, N, Krumholz, HM, Parikh, CR, Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 172 (2012), 761–769.
Davies, M, Chatterjee, S, Khunti, K, The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol 8 (2016), 61–81.
Tong, L, Adler, S, Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. Postgrad Med 130 (2018), 381–393.
Neumiller, JJ, Alicic, RZ, Tuttle, KR, Therapeutic considerations for antihyperglycemic agents in diabetic kidney disease. J Am Soc Nephrol 28 (2017), 2263–2274.
Goldenberg, RM, Berall, M, Chan, CTM, Cherney, DZI, Lovshin, JA, McFarlane, PA, et al. Managing the course of diabetic kidney disease: from the old to the new. Can J Diabetes 42 (2018), 325–334.
Thomas, MC, The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diabetes Metab, 43(Suppl 1), 2017 2S20–2S27.
Fioretto, P, Zambon, A, Rossato, M, Busetto, L, Vettor, R, SGLT2 inhibitors and the diabetic kidney. Diabetes Care 39:Suppl 2 (2016), S165–S171.
Nespoux, J, Vallon, V, SGLT2 inhibition and kidney protection. Clin Sci (Lond) 132 (2018), 1329–1339.
Alicic, RZ, Johnson, EJ, Tuttle, KR, SGLT2 Inhibition for the prevention and treatment of diabetic kidney disease: a review. Am J Kidney Dis 72 (2018), 267–277.
Heerspink, HJL, Kosiborod, M, Inzucchi, SE, Cherney, DZI, Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 94 (2018), 26–39.
Rajani, R, Pastor-Soler, NM, Hallows, KR, Role of AMP-activated protein kinase in kidney tubular transport, metabolism, and disease. Curr Opin Nephrol Hypertens 26 (2017), 375–383.
Allouch, S, Munusamy, S, AMP-activated protein kinase as a drug target in chronic kidney disease. Curr Drug Targets 19 (2018), 709–720.
Ravindran, S, Kuruvilla, V, Wilbur, K, Munusamy, S, Nephroprotective effects of metformin in diabetic nephropathy. J Cell Physiol 232 (2017), 731–742.
Kim, H, Moon, SY, Kim, JS, Baek, CH, Kim, M, Min, JY, et al. Activation of AMP-activated protein kinase inhibits ER stress and renal fibrosis. Am J Physiol Renal Physiol 308 (2015), F226–F236.
Langer, S, Kreutz, R, Eisenreich, A, Metformin modulates apoptosis and cell signaling of human podocytes under high glucose conditions. J Nephrol 29 (2016), 765–773.
Feng, Y, Wang, S, Zhang, Y, Xiao, H, Metformin attenuates renal fibrosis in both AMPKalpha2-dependent and independent manners. Clin Exp Pharmacol Physiol 44 (2017), 648–655.
Lee, M, Katerelos, M, Gleich, K, Galic, S, Kemp, BE, Mount, PF, et al. Phosphorylation of Acetyl-CoA carboxylase by AMPK reduces renal fibrosis and is essential for the anti-fibrotic effect of metformin. J Am Soc Nephrol 29 (2018), 2326–2336 [Epub].
Eisenreich, A, Leppert, U, Update on the protective renal effects of metformin in diabetic nephropathy. Curr Med Chem 24 (2017), 3397–3412.
Rogacka, D, Audzeyenka, I, Rychlowski, M, Rachubik, P, Szrejder, M, Angielski, S, et al. Metformin overcomes high glucose-induced insulin resistance of podocytes by pleiotropic effects on SIRT1 and AMPK. Biochim Biophys Acta 1864 (2018), 115–125.
Neven, E, Vervaet, B, Brand, K, Gottwald-Hostalek, U, Opdebeeck, B, De Mare, A, et al. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder. Kidney Int 94 (2018), 102–113.
Tain, YL, Hsu, CN, AMP-activated protein kinase as a reprogramming strategy for hypertension and kidney disease of developmental origin. Int J Mol Sci, 19, 2018, 10.3390/ijms19061744 [pii: E1744].
UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 854–865.
Lachin, JM, Viberti, G, Zinman, B, Haffner, SM, Aftring, RP, Paul, G, et al. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol 6 (2011), 1032–1040.
Crowley, MJ, Diamantidis, CJ, McDuffie, JR, Cameron, CB, Stanifer, JW, Mock, CK, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med 166 (2017), 191–200.
Inzucchi, SE, Lipska, KJ, Mayo, H, Bailey, CJ, McGuire, DK, Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312 (2014), 2668–2675.
De Broe, ME, Kajbaf, F, Lalau, JD, Renoprotective effects of metformin. Nephron 138 (2018), 261–274.
Diwan, V, Gobe, G, Brown, L, Glibenclamide improves kidney and heart structure and function in the adenine-diet model of chronic kidney disease. Pharmacol Res 79 (2014), 104–110.
Zhang, G, Lin, X, Zhang, S, Xiu, H, Pan, C, Cui, W, A protective role of glibenclamide in inflammation-associated injury. Mediators Inflamm, 2017, 2017, 3578702.
Perkovic, V, Heerspink, HL, Chalmers, J, Woodward, M, Jun, M, Li, Q, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 83 (2013), 517–523.
Wong, MG, Perkovic, V, Chalmers, J, Woodward, M, Li, Q, Cooper, ME, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39 (2016), 694–700.
Masica, AL, Ewen, E, Daoud, YA, Cheng, D, Franceschini, N, Kudyakov, RE, et al. Comparative effectiveness research using electronic health records: impacts of oral antidiabetic drugs on the development of chronic kidney disease. Pharmacoepidemiol Drug Saf 22 (2013), 413–422.
Hung, AM, Roumie, CL, Greevy, RA, Liu, X, Grijalva, CG, Murff, HJ, et al. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int 81 (2012), 698–706.
Hung, AM, Roumie, CL, Greevy, RA, Liu, X, Grijalva, CG, Murff, HJ, et al. Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control. Pharmacoepidemiol Drug Saf 22 (2013), 623–631.
Marcum, ZA, Forsberg, CW, Moore, KP, de Boer, IH, Smith, NL, Boyko, EJ, et al. Mortality associated with metformin versus sulfonylurea initiation: a cohort study of Veterans with diabetes and chronic kidney disease. J Gen Intern Med 33 (2018), 155–165.
Goldshtein, I, Karasik, A, Melzer-Cohen, C, Engel, SS, Yu, S, Sharon, O, et al. Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: a real-world evidence study. J Diabetes Complications 30 (2016), 1354–1359.
Lee, YH, Lee, CJ, Lee, HS, Choe, EY, Lee, BW, Ahn, CW, et al. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice. Diabetes Metab 41 (2015), 208–215.
Sato, H, Shiina, N, Effect of an alpha-glucosidase inhibitor on glomerular basement membrane anionic sites in streptozotocin induced mildly diabetic rats. Diabetes Res Clin Pract 37 (1997), 91–99.
Kim, DM, Ahn, CW, Park, JS, Cha, BS, Lim, SK, Kim, KR, et al. An implication of hypertriglyceridemia in the progression of diabetic nephropathy in metabolically obese, normal weight patients with type 2 diabetes mellitus in Korea. Diabetes Res Clin Pract 66:1 (2004), 169–172.
Chen, YH, Tarng, DC, Chen, HS, Renal outcomes of pioglitazone compared with acarbose in diabetic patients: a randomized controlled study. PLOS One, 11, 2016, e0165750.
Holman, RR, Coleman, RL, Chan, JCN, Chiasson, JL, Feng, H, Ge, J, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 5 (2017), 877–886.
Scheen, AJ, Esser, N, Paquot, N, Antidiabetic agents: potential anti-inflammatory activity beyond glucose control. Diabetes Metab 41 (2015), 183–194.
Tesch, GH, Diabetic nephropathy – is this an immune disorder?. Clin Sci (Lond) 131 (2017), 2183–2199.
Sarafidis, PA, Georgianos, PI, Lasaridis, AN, PPAR-gamma agonism for cardiovascular and renal protection. Cardiovasc Ther 29 (2011), 377–384.
Sarafidis, PA, Bakris, GL, Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 70 (2006), 1223–1233.
Sarafidis, PA, Stafylas, PC, Georgianos, PI, Saratzis, AN, Lasaridis, AN, Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 55 (2010), 835–847.
Agarwal, R, Saha, C, Battiwala, M, Vasavada, N, Curley, T, Chase, SD, et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int 68 (2005), 285–292.
Chang, YH, Hwu, DW, Chang, DM, An, LW, Hsieh, CH, Lee, YJ, Renal function preservation with pioglitazone or with basal insulin as an add-on therapy for patients with type 2 diabetes mellitus. Acta Diabetol 54 (2017), 561–568.
Pistrosch, F, Herbrig, K, Kindel, B, Passauer, J, Fischer, S, Gross, P, Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54 (2005), 2206–2211.
Schneider, CA, Ferrannini, E, Defronzo, R, Schernthaner, G, Yates, J, Erdmann, E, Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 19 (2008), 182–187.
Bolignano, D, Zoccali, C, Glitazones in chronic kidney disease: potential and concerns. Nutr Metab Cardiovasc Dis 22 (2012), 167–175.
Kernan, WN, Viscoli, CM, Furie, KL, Young, LH, Inzucchi, SE, Gorman, M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374 (2016), 1321–1331.
Scheen, AJ, Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res 122 (2018), 1439–1459.
Trevisan, R, The role of vildagliptin in the therapy of type 2 diabetic patients with renal dysfunction. Diabetes Ther 8 (2017), 1215–1226.
Walker, SR, Komenda, P, Khojah, S, Al-Tuwaijri, W, MacDonald, K, Hiebert, B, et al. Dipeptidyl peptidase-4 inhibitors in chronic kidney disease: a systematic review of randomized clinical trials. Nephron 136 (2017), 85–94.
Kamiya, H, A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease. Hemodial Int 21 (2017), 72–83.
Scheen, AJ, Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet 54 (2015), 1–21.
Howse, PM, Chibrikova, LN, Twells, LK, Barrett, BJ, Gamble, JM, Safety and efficacy of incretin-based therapies in patients with type 2 diabetes mellitus and CKD: a systematic review and meta-analysis. Am J Kidney Dis 68 (2016), 733–742.
Scheen, AJ, Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 12 (2010), 648–658.
Scheen, AJ, Delanaye, P, Renal outcomes with dipeptidyl peptidase-4 inhibitors. Diabetes Metab 44 (2018), 101–111.
Penno, G, Garofolo, M, Del Prato, S, Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Nutr Metab Cardiovasc Dis 26 (2016), 361–373.
Coppolino, G, Leporini, C, Rivoli, L, Ursini, F, di Paola, ED, Cernaro, V, et al. Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials. Pharmacol Res 129 (2018), 274–294.
Scheen, AJ, Cardiovascular effects of gliptins. Nat Rev Cardiol 10 (2013), 73–84.
Tonneijck, L, Smits, MM, Muskiet, MH, Hoekstra, T, Kramer, MH, Danser, AH, et al. Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 39 (2016), 2042–2050.
Green, JB, Bethel, MA, Armstrong, PW, Buse, JB, Engel, SS, Garg, J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
Cornel, JH, Bakris, GL, Stevens, SR, Alvarsson, M, Bax, WA, Chuang, LM, et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care 39 (2016), 2304–2310.
Scirica, BM, Bhatt, DL, Braunwald, E, Steg, PG, Davidson, J, Hirshberg, B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
Mosenzon, O, Leibowitz, G, Bhatt, DL, Cahn, A, Hirshberg, B, Wei, C, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care 40 (2017), 69–76.
Udell, JA, Bhatt, DL, Braunwald, E, Cavender, MA, Mosenzon, O, Steg, PG, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 38 (2015), 696–705.
White, WB, Cannon, CP, Heller, SR, Nissen, SE, Bergenstal, RM, Bakris, GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
Groop, PH, Cooper, ME, Perkovic, V, Emser, A, Woerle, HJ, von Eynatten, M, Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 36 (2013), 3460–3468.
Cooper, ME, Perkovic, V, McGill, JB, Groop, PH, Wanner, C, Rosenstock, J, et al. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis 66 (2015), 441–449.
Groop, PH, Cooper, ME, Perkovic, V, Hocher, B, Kanasaki, K, Haneda, M, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab 19 (2017), 1610–1619.
Lajara, R, The MARLINA-T2D trial: putting the results into clinical perspective. Expert Rev Endocrinol Metab 13 (2018), 173–176.
Rosenstock, J, Perkovic, V, Alexander, JH, Cooper, ME, Marx, N, Pencina, MJ, et al. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA ® ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovasc Diabetol, 17, 2018, 39.
Muskiet, MHA, Tonneijck, L, Smits, MM, van Baar, MJB, Kramer, MHH, Hoorn, EJ, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nature Rev Nephrol 13 (2017), 605–628.
Crajoinas, RO, Oricchio, FT, Pessoa, TD, Pacheco, BP, Lessa, LM, Malnic, G, et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 301 (2011), F355–F363.
Fujita, H, Morii, T, Fujishima, H, Sato, T, Shimizu, T, Hosoba, M, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 85 (2014), 579–589.
Li, YK, Ma, DX, Wang, ZM, Hu, XF, Li, SL, Tian, HZ, et al. The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis. Pharmacol Res 131 (2018), 102–111.
Bloomgarden, Z, The kidney and cardiovascular outcome trials. J Diabetes 10 (2018), 88–89.
Skov, J, Pedersen, M, Holst, JJ, Madsen, B, Goetze, JP, Rittig, S, et al. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes Metab 18 (2016), 581–589.
Marso, SP, Daniels, GH, Brown-Frandsen, K, Kristensen, P, Mann, JF, Nauck, MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
Mann, JFE, Orsted, DD, Brown-Frandsen, K, Marso, SP, Poulter, NR, Rasmussen, S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377 (2017), 839–848.
Marso, SP, Bain, SC, Consoli, A, Eliaschewitz, FG, Jodar, E, Leiter, LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
Holman, RR, Bethel, MA, Mentz, RJ, Thompson, VP, Lokhnygina, Y, Buse, JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377 (2017), 1228–1239.
Muskiet, MHA, Tonneijck, L, Huang, Y, Liu, M, Saremi, A, Heerspink, HJL, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 6 (2018), 859–869.
Tuttle, KR, Dwight McKinney, T, Davidson, JA, Anglin, G, Harper, KD, Botros, FT, Effects of once weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. Diabetes Obes Metab 19 (2017), 436–441.
Tuttle, KR, Lakshmanan, MC, Rayner, B, Busch, RS, Zimmermann, AG, Woodward, DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 6 (2018), 605–617.
Boye, KS, Mody, R, Wu, J, Lage, MJ, Botros, FT, Woodward, B., Effects of dulaglutide and insulin glargine on estimated glomerular filtration rate in a real-world setting. Clin Ther 40 (2018), 1396–1407.
Cherney, DZI, Verma, S, Parker, JD, Dulaglutide and renal protection in type 2 diabetes. Lancet Diabetes Endocrinol 6 (2018), 588–590.
Hernandez, AF, Green, JB, Janmohamed, S, D'Agostino, RB Sr, Granger, CB, Jones, NP, et al. Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, 2018, 10.1016/S0140-6736(18)32261-X [Epub ahead of print, pii: S0140-6736(18)32261-X].
Dicembrini, I, Nreu, B, Scatena, A, Andreozzi, F, Sesti, G, Mannucci, E, et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol 54 (2017), 933–941.
Gargiulo, P, Savarese, G, D'Amore, C, De Martino, F, Lund, LH, Marsico, F, et al. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: a meta-analysis. Nutr Metab Cardiovasc Dis 27 (2017), 1081–1088.
Avgerinos, I, Karagiannis, T, Malandris, K, Liakos, A, Mainou, M, Bekiari, E, et al. Glucagon-like peptide 1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab, 2018, 10.1111/dom.13484 [Epub ahead of print].
Bethel, MA, Patel, RA, Merrill, P, Lokhnygina, Y, Buse, JB, Mentz, RJ, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6 (2018), 105–113.
Scheen, AJ, GLP-1 receptor agonists and cardiovascular protection. Class effect or not?. Diabetes Metab 44 (2018), 193–196.
Scheen, AJ, Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75 (2015), 33–59.
Scheen, AJ, Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. Diabetes Metab 42 (2016), 71–76.
Kimura, T, Sanada, J, Shimoda, M, Hirukawa, H, Fushimi, Y, Nishioka, M, et al. Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension. J Diabetes Investig 9 (2018), 875–881.
de Albuquerque Rocha, N, Neeland, IJ, McCullough, PA, Toto, RD, McGuire, DK, Effects of sodium glucose co-transporter 2 inhibitors on the kidney. Diab Vasc Dis Res 15 (2018), 375–386 [Epub:1479164118783756].
Heerspink, HJ, Perkins, BA, Fitchett, DH, Husain, M, Cherney, DZ, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects. Potential mechanisms and clinical applications. Circulation 134 (2016), 752–772.
van Bommel, EJ, Muskiet, MH, Tonneijck, L, Kramer, MH, Nieuwdorp, M, van Raalte, DH, SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome. Clin J Am Soc Nephrol 12 (2017), 700–710.
Mima, A, Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. J Diabetes Complications 32 (2018), 720–725.
Skrtic, M, Cherney, DZ, Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 24 (2015), 96–103.
Mende, CW, Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Curr Med Res Opin 33 (2017), 541–551.
Bonnet, F, Scheen, AJ, Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: potential contribution for diabetic complications and cardiovascular disease. Diabetes Metab, 2018, 10.1016/j.diabet.2018.09.005 [Epub: in press, pii: S1262-3636(18)30176-9].
Dekkers, CCJ, Petrykiv, S, Laverman, GD, Cherney, DZ, Gansevoort, RT, Heerspink, HJL, Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab 20 (2018), 1988–1993.
Yoshimoto, T, Furuki, T, Kobori, H, Miyakawa, M, Imachi, H, Murao, K, et al. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes. J Investig Med 65 (2017), 1057–1061.
Zhao, Y, Xu, L, Tian, D, Xia, P, Zheng, H, Wang, L, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 20 (2018), 458–462.
Zinman, B, Wanner, C, Lachin, JM, Fitchett, D, Bluhmki, E, Hantel, S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
De Cosmo, S, Viazzi, F, Pacilli, A, Giorda, C, Ceriello, A, Gentile, S, et al. Serum uric acid and risk of CKD in type 2 diabetes. Clin J Am Soc Nephrol 10 (2015), 1921–1929.
Wang, J, Yu, Y, Li, X, Li, D, Xu, C, Yuan, J, et al. Serum uric acid levels and decreased estimated glomerular filtration rate in patients with type 2 diabetes: a cohort study and meta-analysis. Diabetes Metab Res Rev, 34, 2018, e3046 [Epub: e3046].
Scheen, AJ, Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet 54 (2015), 691–708.
Barnett, AH, Mithal, A, Manassie, J, Jones, R, Rattunde, H, Woerle, HJ, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2 (2014), 369–384.
Cherney, DZI, Cooper, ME, Tikkanen, I, Pfarr, E, Johansen, OE, Woerle, HJ, et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA 1c reductions with empagliflozin. Kidney Int 93 (2018), 231–244.
Dekkers, CCJ, Wheeler, DC, Sjostrom, CD, Stefansson, BV, Cain, V, Heerspink, HJL, Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and stages 3b-4 chronic kidney disease. Nephrol Dial Transplant, 33, 2018, 1280.
Wanner, C, Lachin, JM, Inzucchi, SE, Fitchett, D, Mattheus, M, George, J, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137 (2018), 119–129.
Neuen, BL, Ohkuma, T, Neal, B, Matthews, DR, de Zeeuw, D, Mahaffey, KW, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function: data from the CANVAS program. Circulation, 2018, 10.1161/CIRCULATIONAHA.118.035901 [Epub ahead of print, pii: CIRCULATIONAHA.118.035901].
Mazidi, M, Rezaie, P, Gao, HK, Kengne, AP, Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22,528 patients. J Am Heart Assoc, 6, 2017, 10.1161/JAHA.116.004007 [pii: e004007].
Scheen, AJ, Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes : focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Res Clin Pract 121 (2016), 204–214.
Scheen, AJ, Delanaye, P, Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes : focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Metab 43 (2017), 99–109.
Wanner, C, Inzucchi, SE, Lachin, JM, Fitchett, D, von Eynatten, M, Mattheus, M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
Cherney, DZI, Zinman, B, Inzucchi, SE, Koitka-Weber, A, Mattheus, M, von Eynatten, M, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5 (2017), 610–621.
Neal, B, Perkovic, V, Mahaffey, KW, de Zeeuw, D, Fulcher, G, Erondu, N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
Perkovic, V, Zeeuw, D, Mahaffey, KW, Fulcher, G, Erondu, N, Shaw, W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 6 (2018), 691–704.
Mahaffey, KW, Neal, B, Perkovic, V, de Zeeuw, D, Fulcher, G, Erondu, N, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation 137 (2018), 323–334.
Heerspink, HJ, Desai, M, Jardine, M, Balis, D, Meininger, G, Perkovic, V, Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28 (2017), 368–375.
Takashima, H, Yoshida, Y, Nagura, C, Furukawa, T, Tei, R, Maruyama, T, et al. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: a randomized open-label prospective trial. Diab Vasc Dis Res 15 (2018), 469–472.
Jardine, MJ, Mahaffey, KW, Neal, B, Agarwal, R, Bakris, GL, Brenner, BM, et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 46 (2017), 462–472.
Fioretto, P, Stefansson, BV, Johnsson, E, Cain, VA, Sjostrom, CD, Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia 59 (2016), 2036–2039.
Scheen, AJ, SGLT2 inhibitors: benefit/risk balance. Curr Diabetes Rep, 16, 2016, 92.
Wanner, C, EMPA-REG OUTCOME: the nephrologist's point of view. Am J Cardiol 120 (2017), S59–S67.
Szalat, A, Perlman, A, Muszkat, M, Khamaisi, M, Abassi, Z, Heyman, SN, Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf 41 (2018), 239–252.
Perlman, A, Heyman, SN, Matok, I, Stokar, J, Muszkat, M, Szalat, A, Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis 27 (2017), 1108–1113.
Saly, DL, Perazella, MA, Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity. Am J Physiol Renal Physiol 313 (2017), 951–954.
Tang, H, Li, D, Zhang, J, Li, Y, Wang, T, Zhai, S, et al. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 19 (2017), 1106–1115.
Hills, CE, Brunskill, NJ, Squires, PE, C-peptide as a therapeutic tool in diabetic nephropathy. Am J Nephrol 31 (2010), 389–397.
Yosten, GL, Maric-Bilkan, C, Luppi, P, Wahren, J, Physiological effects and therapeutic potential of proinsulin C-peptide. Am J Physiol Endocrinol Metab 307 (2014), E955–E968.
Coward, R, Fornoni, A, Insulin signaling: implications for podocyte biology in diabetic kidney disease. Curr Opin Nephrol Hypertens 24 (2015), 104–110.
Hale, LJ, Coward, RJ, Insulin signalling to the kidney in health and disease. Clin Sci (Lond) 124 (2013), 351–370.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
Bilous, R, Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?. Diabet Med 25:Suppl 2 (2008), 25–29.
Zoungas, S, Arima, H, Gerstein, HC, Holman, RR, Woodward, M, Reaven, P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 5 (2017), 431–437.
ORIGIN trial investigators, Gilbert, RE, Mann, JF, Hanefeld, M, Spinas, G, Bosch, J, et al. Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia 57 (2014), 1325–1331.
Currie, CJ, Poole, CD, Evans, M, Peters, JR, Morgan, CL, Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 98 (2013), 668–677.
Hung, AM, Roumie, CL, Greevy, RA, Grijalva, CG, Liu, X, Murff, HJ, et al. Comparative effectiveness of second-line agents for the treatment of diabetes type 2 in preventing kidney function decline. Clin J Am Soc Nephrol 11 (2016), 2177–2185.
Delanaye, P, Scheen, AJ, Preventing and treating kidney disease in patients with type 2 diabetes. Expert Opin Pharmacother, 2018 [in press].
DeFronzo, RA, Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab 19 (2017), 1353–1362.
DeFronzo, RA, Chilton, R, Norton, L, Clarke, G, Ryder, RE, Abdul-Ghani, M, Revitalization of pioglitazone: the optimal agent to be combined with an SGLT2 inhibitor. Diabetes Obes Metab 18 (2016), 454–462.
Davies, MJ, D'Alessio, DA, Fradkin, J, Kernan, WN, Mathieu, C, Mingrone, G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2018, 10.1007/s00125-018-4729-5.